Abstract:

 Objective  To observe the expression status of CCL20 and CCR6 in cancer tissue of patients with recurrent and non-recurrent lung adenocarcinoma and explore the effects of CCL20 and CCR6 in the development of the disease.

 Methods  162 lung adenocarcinoma patients who received treatment in Hebei General Hospital from February 2009 to December 2011 were selected.The patients were divided into recurrent group(n=50) and non-recurrent group(n=112) according to their recurrence and metastasis conditions.The expression,the mRNA expression and the protein expression of CCL20 and CCR6 were detected by immunohistochemistry staining,real-time PCR and Western-blot method respectively.

 Results  CCL20 was mainly expressed in cell membrane and cytoplasm of lung adenocarcinoma tissue,while CCR6 expressed in cytoplasm of lung adenocarcinoma tissue.The two had no significant expression in para-carcinoma tissue of lung adenocarcinoma.The high-expression ratio and the staining index of CCL20 and CCR6 in recurrent group was significantly higher than those of the non-recurrent group(P＜0.05).The high-expression ratio of CCL20 and of CCR6 between recurrent and non-recurrent group were 38(76.0%) to 9(8.0%) and 33(66.0%) to 7(6.3%) separately;and the staining index of CCL20 and CCR6 between the two groups were(150.4±10.2) to(62.5±8.5) and(134.4±11.3) to(58.0±9.5) respectively.Compared with non-recurrent group,the mRNA expression of CCL20 and CCR6 in recurrent group increased by 82.3% and 56.4% respectively,the protein expression of CCL20 and CCR6 increased by 292.0% and 188.0% respectively,showing significant differences(P＜0.05).

 Conclusion  Presenting high expression in lung adenocarcinoma tissue,CCL20 and CCR6 are related with the development of lung adenocarcinoma.

Key words:

font-family: 宋体, mso-spacerun: 'yes', mso-font-kerning: 1.0000pt">  Lung neoplasms;Chemokine CCL20;Receptors,CCR6;Recurrence;Neoplasm metastasis   

摘要：

目的  通过观察复发和非复发肺腺癌患者癌组织中CCL20和CCR6的表达情况，探讨CCL20和CCR6在肺腺癌发生发展中的作用。 方法  选取2009年2月—2011年12月河北省人民医院收治的肺腺癌患者162例，根据随访期间的复发转移情况分为复发组（n=50）和非复发组（n=112）。采用免疫组织化学染色检测CCL20和CCR6的表达；采用实时荧光定量PCR检测CCL20、CCR6 mRNA的表达，采用蛋白质印迹（Western blot）法检测CCL20、CCR6蛋白的表达。 结果  CCL20在肺腺癌组织中主要表达于细胞膜和细胞质，CCR6在肺腺癌组织中主要表达于细胞质，二者在肺腺癌癌旁组织中均无明显表达。复发组CCL20、CCR6高表达率〔CCL20：38（76.0%）比9（8.0%）；CCR6：33（66.0%）比7（6.3%）〕和染色指数〔CCL20：（150.4±10.2）比（62.5±8.5）；CCR6：（134.4±11.3）比（58.0±9.5）〕均高于非复发组，差异有统计学意义（P＜0.05）。复发组CCL20、CCR6 mRNA表达较非复发组分别增加82.3%、56.4%，CCL20、CCR6蛋白表达较非复发组分别增加292.0%、188.0%，差异均有统计学意义（P＜0.05）。 结论  CCL20和CCR6在肺腺癌组织中呈高表达，且与肺腺癌的发生发展相关。

关键词:

font-family: 宋体, mso-spacerun: 'yes', mso-font-kerning: 1.0000pt">肺肿瘤, 趋化因子CCL20, 受体, CCR6, 复发, 肿瘤转移